TY - JOUR
T1 - Late Varicella-Zoster Virus Dendriform Keratitis in Patients With Histories of Herpes Zoster Ophthalmicus
AU - Hu, Allen Y.H.
AU - Strauss, Erich C.
AU - Holland, Gary N.
AU - Chan, Matilda F.
AU - Yu, Fei
AU - Margolis, Todd P.
N1 - Funding Information:
This study was supported by Research to Prevent Blindness (RPB), Inc, New York, New York (Drs Strauss and Holland), National Institute of Health, Bethesda, Maryland, grants EY014419 (Dr Strauss) and EY018858 (Dr Chan), the Francis I. Proctor Foundation, University of California, San Francisco Ocular Immunology Fund (Dr Strauss), the Skirball Foundation, New York, New York (Dr Holland), the Vernon O. Underwood Family Endowed Professorship (Dr Holland), and the Littlefield Foundation, El Sobrante, California (Dr Margolis). Additional support was provided by the Emily Plumb Estate and Trust Gift for resources utilized in the Jules Stein Eye Institute Clinical Research Center, Los Angeles, California. Dr Strauss is recipient of an RPB James S. Adams Scholar Award. Dr Holland is recipient of an RPB Physician-Scientist Award.
PY - 2010/2/1
Y1 - 2010/2/1
N2 - Purpose: To describe the characteristics and course of late varicella-zoster virus (VZV) dendriform keratitis in patients with histories of herpes zoster ophthalmicus (HZO); to describe responses of corneal lesions to antiviral treatment; and to investigate risk factors for recurrence. Design: Retrospective case series. Methods: Included were patients known to have 1 or more episodes of dendriform lesions beginning at least 2 weeks after HZO in 2 academic practices. Epithelial lesions were evaluated for the presence of VZV DNA by a polymerase chain reaction assay. Demographic, medical, and ophthalmic data were collected for each episode. Responses to treatment with antiviral medications were evaluated. Cumulative risk of recurrence was determined using Kaplan-Meier analysis; potential risk factors for recurrence (age, systemic disease, lesion characteristics, corticosteroids) were evaluated using univariate Cox proportional hazard models. Results: We identified 20 patients (14 women; median age, 65 years) who met inclusion criteria. Dendriform lesions were pleomorphic with thickened, opaque epithelium. Seven patients had systemic diseases characterized by altered immune function. VZV DNA was identified in 15 of 16 cases tested, and all lesions responded to antiviral therapy. The 1-year incidence of first recurrence was 95.8 lesions per 100 person-years of follow-up. Patients had multiple recurrences, but risk of recurrence appeared to decrease over time. No statistically significant risk factors for recurrence were identified. Conclusions: Late dendriform lesions associated with HZO are foci of productive VZV infection. Lesions can be treated effectively with topical or systemic antiviral agents. Patients can have multiple recurrences of dendriform lesions despite treatment.
AB - Purpose: To describe the characteristics and course of late varicella-zoster virus (VZV) dendriform keratitis in patients with histories of herpes zoster ophthalmicus (HZO); to describe responses of corneal lesions to antiviral treatment; and to investigate risk factors for recurrence. Design: Retrospective case series. Methods: Included were patients known to have 1 or more episodes of dendriform lesions beginning at least 2 weeks after HZO in 2 academic practices. Epithelial lesions were evaluated for the presence of VZV DNA by a polymerase chain reaction assay. Demographic, medical, and ophthalmic data were collected for each episode. Responses to treatment with antiviral medications were evaluated. Cumulative risk of recurrence was determined using Kaplan-Meier analysis; potential risk factors for recurrence (age, systemic disease, lesion characteristics, corticosteroids) were evaluated using univariate Cox proportional hazard models. Results: We identified 20 patients (14 women; median age, 65 years) who met inclusion criteria. Dendriform lesions were pleomorphic with thickened, opaque epithelium. Seven patients had systemic diseases characterized by altered immune function. VZV DNA was identified in 15 of 16 cases tested, and all lesions responded to antiviral therapy. The 1-year incidence of first recurrence was 95.8 lesions per 100 person-years of follow-up. Patients had multiple recurrences, but risk of recurrence appeared to decrease over time. No statistically significant risk factors for recurrence were identified. Conclusions: Late dendriform lesions associated with HZO are foci of productive VZV infection. Lesions can be treated effectively with topical or systemic antiviral agents. Patients can have multiple recurrences of dendriform lesions despite treatment.
UR - http://www.scopus.com/inward/record.url?scp=73849134892&partnerID=8YFLogxK
U2 - 10.1016/j.ajo.2009.08.030
DO - 10.1016/j.ajo.2009.08.030
M3 - Article
C2 - 19909942
AN - SCOPUS:73849134892
SN - 0002-9394
VL - 149
SP - 214-220.e3
JO - American journal of ophthalmology
JF - American journal of ophthalmology
IS - 2
ER -